BFNH (BioForce Nanosciences Holdings) EBIT: $-0.48 Mil (TTM As of Mar. 2026)

What is BioForce Nanosciences Holdings EBIT?

BioForce Nanosciences Holdings BFNH 34 EBIT is $-0.48 Mil as of Mar. 2026. GuruFocus rates BFNH with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

BioForce Nanosciences Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.12 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.48 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioForce Nanosciences Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -84.82%. BioForce Nanosciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioForce Nanosciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -0.86%.

BioForce Nanosciences Holdings (OTCPK:BFNH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioForce Nanosciences Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-0.472 * ( 1 - 0% )	/	( (0.506	+	0.607)	/ 2 )
=	-0.472	/	0.5565
=	-84.82 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.001	-	0.113	-	( 0.001	-	max(0, 0.619	-	0.001	+	0.001	))
=	0.506

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.006	-	0.12	-	( 0.006	-	max(0, 0.727	-	0.006	+	0.006	))
=	0.607

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

BioForce Nanosciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.472	/	( ( (0 + max(-0.619, 0))	+	(0 + max(-0.727, 0)) )	/	2 )
=	-0.472	/	( ( 0	+	0 )	/	2 )
=	-0.472	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.113	+	0	+	0.506)
=	-0.619

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.12	+	0	+	0.607)
=	-0.727

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioForce Nanosciences Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-0.475	/	55.350
	=	-0.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioForce Nanosciences Holdings EBIT Related Terms

BioForce Nanosciences Holdings EBIT Historical Data

* Premium members only.

The historical data trend for BioForce Nanosciences Holdings's EBIT can be seen below:

BioForce Nanosciences Holdings EBIT Chart

BioForce Nanosciences Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-0.50

-0.49

-0.47

-0.49

BioForce Nanosciences Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-0.13	-0.12	-0.12	-0.12	-0.12

BFNH vs WYGC, HRGN, STCB: EBIT Comparison

For the Packaged Foods subindustry, BioForce Nanosciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioForce Nanosciences Holdings EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioForce Nanosciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioForce Nanosciences Holdings's EV-to-EBIT falls into.

Save Embed

34GF Score

BioForce Nanosciences Holdings Inc BFNH

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioForce Nanosciences Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-0.48 Mil mean?

BioForce Nanosciences Holdings (BFNH) has a EBIT of $-0.48 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioForce Nanosciences Holdings.

Is BioForce Nanosciences Holdings' EBIT too high?

BioForce Nanosciences Holdings' current EBIT is $-0.48 Mil. Overall, BioForce Nanosciences Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does BioForce Nanosciences Holdings' EBIT compare to WYGC and HRGN?

BioForce Nanosciences Holdings' EBIT of $-0.48 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Consumer Packaged Goods company?

A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioForce Nanosciences Holdings. BioForce Nanosciences Holdings's current EBIT is $-0.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioForce Nanosciences Holdings stock overvalued right now?

BioForce Nanosciences Holdings (BFNH) has a current EBIT of $-0.48 Mil. The current EBIT is $-0.48 Mil. BioForce Nanosciences Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For BioForce Nanosciences Holdings (BFNH), the current EBIT is $-0.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioForce Nanosciences Holdings Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies WYGC HRGN STCB DTEAF JVA LIMX FAMI COOT CTGL NAII XSWX:NESN XPAR:BN BOG:NUTRESA TSE:2802 SHSE:603288 NSE:NESTLEIND KHC SHSE:600887 SZSE:300999 GIS

Address 2020 General Booth Boulevard, Suite 230, Virginia Beach, VA, USA, 23454

Website https://www.bioforceeclipse.com

BioForce Nanosciences Holdings Inc is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages. It markets its products through social media and telemarketing. BioForce currently markets its products through social media and telemarketing. Nutrition retailers, grocery stores, retail pharmacies, and online stores, like Amazon, will be important channels for the Company's Eclipse product-lines.

34GF Score

Get the complete analysis for BFNH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65

Price

View BFNH Analysis

See EBIT data for all stocks →